Aug 15
Opportunity
Clinical trial participants may have many questions and concerns during and after the clinical trial. To help address participants’ questions / concerns in a timely manner, support (e.g., phone number to call, in-app support, virtual bot) can allow clinical trial participants to receive answers and reassurance without needing to wait for the next scheduled visit.
Considerations to Help Action the Opportunity
- Partner with investigative sites to ensure understanding of currently available site contact support and what support sites may need to enable flexibility
- Identify multiple options for a participant to contact / stay engaged with the investigative site or reach out to a designated contact
- Provide a clear description of which service should be used in each situation and point of contact, if several service options are available
- Offer service(s) in the participant’s native language and make them available 24/7
- Partner with participants / patient organizations to ensure support services are easy to use and fit their needs
- Provide tools and training to enable participant self service
Value and Potential Benefits
- Allows participants to ask questions regarding clinical trial participation when needed, potentially alleviating concerns at the current time rather than waiting for next visit
- May increase participant engagement by allowing stronger connectivity between participants and clinical trial staff
Tools and Resources
- No tools or resources currently available to support this opportunity
Related Blog Posts
Why the biggest gains in clinical R&D won’t come from technology
Every few years, the clinical research industry rallies around a new wave of innovation. From decentralised trials and digital biomarkers to AI driven automation, each wave brings genuine capability andpromise. Read the full article featuring Kelsey Jakee on page 38 here.
Enough, already: the problem with clinical trial data collection
The clinical research ecosystem has never been more technologically capable — or more burdened by its own ambition. In December 2025, the Tufts Center for the Study of Drug Development and our team at TransCelerate published research that suggests nearly 30% of the data collected in clinical trials do not directly inform key decisions, yet patients are…
2026 DIA Global Annual Meeting: What the FDA’s Real-Time Data Push Actually Means for Sponsors and CROs
In this video interview from the 2026 DIA Global Annual Meeting, Kevin Bugin, head of global regulatory policy and intelligence at Amgen and executive sponsor of TransCelerate’s Embedded Pragmatic Trials initiative, reframes the FDA’s continuous review expectations around real-time evidence generation and explains why quality by design—not data cleanup—is what regulators are now demanding. Watch…
